Liquid paraffin 65% / Acetylated wool alcohols 5% bath oil
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Liquid paraffin + Acetylated wool alcohols
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
Part of the Zerolatum brand family (generic: Liquid paraffin + Acetylated wool alcohols)
MHRA licensed products
View all licensed products for Liquid paraffin + Acetylated wool alcohols on the MHRA register
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · 1906–2025
Showing the 50 most relevant studies, sorted by most relevant.
Karin Leontein, Bengt Lindberg, Jörgen Lōnngren
Carbohydrate Research, 1978
Rong Li, Dong Wang
Journal of Applied Polymer Science, 2012
R THORNTON
Journal of Catalysis, 1974
Peter Förster, William Lothar Graf von Westarp, Janik Hense, et al.
2025
Reactions Weekly, 2025
Sathyaki D C, Shwetha Naidu, Nalina P A, et al.
2025
Abstract Objectives Nasal obstruction due to deviated nasal septum is a common problem encountered by otolaryngologists. Septoplasty is the surgical procedure which has been performed in the treatment of the same. This study was conducted to evaluate the efficacy of post operative topical application of liquid paraffin and saline nasal douching. Methods This is a prospective, randomized study. Forty patients with symptomatic deviated nasal septum were included in the study, 20 of them were advised topical application of liquid paraffin and the rest were advised saline nasal douching. Results The difference in the functional outcome of both the irrigation was insignificant. There was a significant difference with respect to formation of crust and synechae. Liquid paraffin had better outcome. Conclusion Topical application of liquid paraffin resulted in prevention of crusting and synechae.
Abstract licence: CC BY 4.0
Priyanka Sangwan, Biswanath Behera, Sonika Garg
Cosmoderma, 2023
Aditi Gopalakrishnan
2025
Soner Kızıl, Buse Ilgım Yosmaoğlu, Sevil Atasoy
Gümüşhane Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.